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Background: It’s unknown whether the prognostic value of admission heart rate (HR) was different in patients with
ST-segment elevation myocardial infarction (STEMI) with or without concomitant type 2 diabetes mellitus (T2DM).
Methods: Consecutive STEMI patients who presented within 12 hours of symptom onset were recruited from 274
hospitals in China. Participants were stratified into quartiles by admission HR. Baseline characteristics, current
therapeutic recommenda- tions, laboratory biochemical tests, 30-day all-cause mortality and Cardiovascular Events
(CVE, including all-cause death, reinfarction and stroke) were compared across admission HR quartiles.
Results: We evaluated 7294 STEMI patients, of these 820 (11.2%) had known T2DM. The admission HR quartile
stratification was significantly associated with all-cause mortality and CVE regardless of T2DM status (P < 0.001 both
for survival and CVE). After adjusted other risk factors, in patients without T2DM, comparing with HR <66 b.p.m., the
increase of HR level was associated with worse prognosis (P < 0.05). In patients with T2DM, the hazard ratios for
30-day CVE were 1.75 (95%CI), 1.92 (95%CI), 3.00 (95%CI) in the HR of 66–76 b.p.m., 77–88 b.p.m., and >88 b.p.m.,
respectively. Results were similar for 30-day all-cause mortality, but the hazard ratios in Q2 (P = 0.139 and P =0.086
for survival and CVE, respectively) and Q3 groups were non-significant (P = 0.072 and P =0.033 for survival and CVE,
respectively). There was a significant interaction effect of HR and T2DM on 30-day CVE mortality (P = 0.035), which
was not found on all-cause mortality (P = 0.126).
Conclusion: Admission heart rate was an important risk factor of 30-day all-cause mortality and CVE in patients
with STEMI with or without T2DM. However, the predictive effect was modified by T2DM.
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Several epidemiological and clinical studies have reported
the association between heart rate (HR) and prognosis in
general population and in patients with hypertension,
stable coronary artery disease (CAD), heart failure (HF)
[1-4], or acute coronary syndromes (ACS) [5,6].
In addition, the relationship between type 2 diabetes
mellitus (T2DM) and prognosis has been well demon-
strated in patients with acute myocardial infarction (AMI)
[7,8]. Cardiac autonomic neuropathy (CAN) and higher HR
may correlated with worse prognosis in diabetic patients
after AMI [9,10]. However, in patients with ST-segment* Correspondence: yymwin@yahoo.com.cn
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reproduction in any medium, provided the orelevation myocardial infarction (STEMI), it is unclear
whether the effect of HR on prognosis will be different be-
tween patients with and without T2DM.
The purpose of our report from a large study is to
evaluate the association between admission HR and 30-
day all-cause mortality and cardiovascular events (CVE)
in STEMI patients with or without T2DM.Methods
Patients
From July 2001 to July 2004, 7510 consecutive patients with
a clinical diagnosis of STEMI were admitted to 247 hospi-
tals throughout China within 12 h of the onset of symptom.
Data were collected and recorded in a research database.
AMI was diagnosed on the basis of the European Society of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[11]. STEMI was defined as AMI with ST-segment eleva-
tion in two contiguous leads or new left-bundle branch
block on an ECG obtained at the time of admission. Only
patients with sinus rhythm were included in analysis.
Patients who were hemodynamically unstable and hospita-
lized with atrial fibrillation, second or third degree heart
block, ventricular tachycardia, ventricular fibrillation and
cardiac arrest were excluded. According to the exclusion
criteria, 99 patients were excluded. 27 patients were
excluded from analysis because of incomplete information.
Data collection
At baseline, demographic characteristics and details of con-
comitant cardiovascular risk factors were recorded. Fur-
thermore, a medical history was taken and fasting plasma
glucose was assessed. HR was measured by a 12-lead ECG
at admission. Qualifying patients received thrombolytic
therapy or underwent percutanous coronary intervention
(PCI) according to current therapeutic recommendations
[12]. In-hospital and 30-day adverse events, including
death, cardiogenic shock, HF, life-threatening arrhythmia
and re-infarction were also recorded in detail.
The presence of known T2DM was recognized if the
diagnosis was established according to the WHO definition
[13] prior to enrollment, reported in the medical records,
declared directly by the patient, or revealed by using the
glucose-lowering medications, for example, metformin.
The follow-up duration was 30 days. Trained study
personnel recorded all outcomes by reviewing the medical
record, telephone or email contact. All-cause mortality
and Cardiovascular Events (CVE, including all-cause
death, reinfarction and stroke) in 30 days, were adjudi-
cated by a central committee of clinicians.
The study was approved by the institutional Ethics com-
mittees at all participating hospitals. Informed consent
was obtained from each patient.
Study outcomes and definition
The primary outcomes were death from cardiac or non-
cardiac cause in 30 days. CVE comprised of all-cause mor-
tality, reinfarction, or stroke. Definitions of outcomes were
as follows:
All-cause mortality included cardiovascular death
(defined as any death with a cardiovascular cause includ-
ing those deaths following cardiovascular procedures or
surgery or deaths due to unknown cardiovascular cause)
and non-cardiovascular death (defined as deaths due to a
clearly documented non-cardiovascular cause).
Reinfarction was defined as the presence of at least two
of the following criteria:
1. New onset of characteristic ischemic chest pain/
symptoms occurring at rest or with minimal exercise;2. Elevation of enzyme levels or markers (CK, CK-MB,
other cardiac enzymes or Troponin I or T) to at least
twice the upper limit of the normal reference range
or if enzymes were already elevated, greater than 50%
of the lowest recovery enzyme level from the index
infarction;
3. New ECG changes compatible with ischemia.
Stroke was defined as the presence of a new focal
neurologic deficit consistent with a vascular origin with
signs or symptoms lasting > 24 hours. Confirmation by
CT scan or MRI is was obtained when available.
Statistical analysis
Continuous variables are expressed as mean ± standard
deviation, and categorical variables as counts and percen-
tages. Admission HR was firstly analyzed as a continuous
variable, and then as a categorical variable (Q1:<66;
Q2:66–76; Q3:77–88; Q4:>88b.p.m., beats per minute).
Differences in baseline characteristics across admission
HR quartiles were evaluated using the one-way analysis
of variance (ANOVA) or Chi-square tests, according to
T2DM status. The Kaplan–Meier curves were computed
for cardiovascular mortality and CVE. The log- rank test
was used to test the differences in the unadjusted survival
curves. Hazard ratios (HRs) were estimated by the Cox
proportional hazard regression model in patients with or
without T2DM and the models were corrected for age,
sex, systolic blood pressure(SBP), previous hypertension,
myocardial infarction, heart failure (CHF), or stroke, ST-
segment elevation leads, killip class, and intervention
measures and drugs. Potential interaction (effect modifi-
cation) between HR and diabetes was evaluated by add-
ing a multiplicative interaction term (HR × diabetes) to
the Cox model.
A two-sided P-value of 0.05 was considered statistically
significant; all analyses were performed with SPSS 17.0
for Windows (SPSS Inc., Chicago, IL, USA).
Results
Of the 7510 patients enrolled between July 2001 and July
2004 from 274 centers across China, data from 7294
patients (97.1%) were available for analysis, and 820
(11.2%) had known T2DM (Figure 1). Overall, median
admission HR was 76 (65–88) b.p.m.; 76 (64–88) b.p.m.
and 80 (68–94.5) b.p.m., respectively, in patients without
and with T2DM.
Baseline characteristics
Comparison of baseline demographic and clinical charac-
teristics in hospital between patients with and without
DM is detailed in Table 1. Patients with T2DM were
older (64.7 ± 9.9 vs 62.3 ± 12.0, P < 0.001) and more of
them were women (43.1% vs 27.1%, P < 0.001). More of
the patients with T2DM were hypertensive (57.4% vs
Figure 1 Flow of study patients.
Han et al. BMC Cardiovascular Disorders 2012, 12:104 Page 3 of 7
http://www.biomedcentral.com/1471-2261/12/10438.5%, P < 0.001), had a previous stroke (16.5% vs 8.4%,
P < 0.001), HF (6.3% vs 2.2%, P < 0.001) or myocardial in-
farction (12.2% vs 7.5%, P < 0.001) compared with
patients without T2DM. T2DM was also associated
with higher admission HR (82.2 ± 19.9 vs 77.2 ± 17.8,
P < 0.001) and fasting serum glucose level (13.2 ± 5.5 vs
7.9 ± 3.6, P < 0.001) and more likely to be treated with
insulin infusion (40.2% vs 11.5%, P < 0.05). Interest-
ingly, participants with T2DM were more likely toTable 1 Baseline characteristics and therapy of study






Females, % 27.1 43.1 <0.001
Age 62.3 ± 12.0 64.7 ± 9.9 <0.001
Systolic blood pressure 126.5 ± 25.1 128.1 ± 26.0 0.039
Admission heart rate 77.2 ± 17.8 82.2 ± 19.9 <0.001
Anterior ST Elevation, % 53.4 52.6 0.633
Killip class II-IV, % 17.1 24.8 <0.001
Glucose Level, mmol/L 7.9 ± 3.6 13.2 ± 5.5 <0.001
Previous medical history
Hypertension, % 38.5 57.4 <0.001
Myocardial Infarction, % 7.5 12.2 <0.001
Heart failure, % 2.2 6.3 <0.001
Stroke, % 8.4 16.5 <0.001
Therapeutic measures
PCI, % 10.9 16.9 <0.001
Thrombolytic therapy 53.3 45.1 <0.001
Insulin 11.5 40.2 <0.001
β-blockers, % 62.1 63.3 0.506
ACEI, % 71.8 73.3 0.367
Lipid-lowering drugs, % 71.1 72.6 0.377
PCI, percutaneous coronary intervention; ACEI, Angiotensin-converting enzyme
inhibitors.receive PCI (16.9% vs 10.9%, P < 0.001), while fewer of
them were treated with thrombolytic therapy (45.1% vs
53.3%, P < 0.001).
Characteristics were reported in Table 2 by HR quartiles
and by diabetic state. It’s similar that previous history of
stroke and serum glucose level were not associated with
admission HR (P > 0.05) in both diabetics and non-
diabetics. Meanwhile, admission HR was associated with
systolic blood pressure, frequency of anterior ST Eleva-
tion, Killip class II-IV, previous history of myocardial in-
farction or heart failure (P < 0.05). In addition, patients
with a higher admission HR were were more likely to be
treated with β-blockers, angiotensin-converting enzyme
inhibitors (ACEI) and percutaneous coronary intervention
(PCI) (P < 0.05) regardless of T2DM status.
In non-T2DM group, patients with higher admission HR
were older, while more of them were women and hyperten-
sive than those with lower admission HR (P < 0.05). They
were more likely to use insulin, and less likely to be treated
with thrombolytic therapy (P < 0.05). However, these differ-
ences across admission HR quartiles were not apparent in
patients accompanied with T2DM.
Primary and secondary outcomes
30-day outcomes were reported in Table 3 grouped by
HR quartiles and by diabetic status. Patients with
T2DM showed higher events rate for 30-day all-cause
mortality (9.6% vs. 15.7%, P < 0.001) and CVE (11.2%
vs. 18.1%, P < 0.001) compared with patients without
T2DM. Events rate for 30-day all-cause mortality and
CVE were higher with an increase of admission HR in
patients independent of T2DM state (P < 0.001).
Kaplan-Meier curves for all-cause mortality and CVE
were shown in Figure 2. The log-rank test reported that
the unadjusted survival curves were not different among
the lower three groups (P > 0.05, multiple comparison
data not shown), while patients in the highest quartile of
admission HR showed the highest rate of mortality and
CVE (P < 0.001), regardless of T2DM.
Multivariable Cox regression analysis was performed
to assess the prognostic value of admission HR after
adjusting for age, sex, the medical history of hyperten-
sion, heart failure, myocardial infarction, stroke, Killip
class, medications and procedures in-hospital (Insulin,
β-blockers, ACEI, lipid-lowering drugs, and PCI). Ana-
lyses with HR as a continuous variable showed that ad-
mission HR was an independent risk factor of 30-day
all-cause mortality (HR, 1.011; 95% CI, 1.008-1.015,
P < 0.001) and CVE (HR, 1.010; 95% CI, 1.006-1.013,
P < 0.001) in overall patients and in patients without
T2DM (for all-cause mortality: HR, 1.013; 95% CI,
1.009-1.017, P < 0.001; for CVE: HR, 1.010; 95% CI,
1.006-1.014, P < 0.001). The similar predictive effect
were found for 30-day CVE (P < 0.05).
Table 2 Baseline characteristics and therapy of non-diabetic patients based on quartiles of admission heart rate
(Q1-Q4)

















Females, % 25.3 25.5 26.8 31.3 <0.001 37.8 43.4 42.0 47.1 0.270
Age 62.3 ± 11.2 61.2 ± 11.9 61.7 ± 12.2 63.0 ± 12.9 <0.001 64.5 ± 9.9 64.0 ± 9.5 64.8 ± 10.2 65.3 ± 9.9 0.313
Systolic blood
pressure
120.0 ± 24.0 128.0 ± 24.0 130.4 ± 23.3 128.5 ± 28.0 <0.001 120.2 ± 26.8 130.2 ± 22.0 130.6 ± 25.2 130.1 ± 27.4 <0.001
Anterior ST Elevation, % 34.4 51.6 62.7 68.5 <0.001 27.2 50.3 57.5 67.3 <0.001
Killip class ≥2, % 13.5 12.6 14.0 29.7 <0.001 15.6 13.7 20.2 41.2 <0.001
Glucose, mmol/L 7.8 ± 3.5 7.7 ± 3.2 7.8 ± 3.5 8.4 ± 4.2 0.097 13.0 ± 5.3 12.6 ± 5.0 12.8 ± 4.8 14.1 ± 6.2 0.054
Previous medical history
Hypertension, % 36.4 36.9 38.7 42.6 0.001 55.6 53.1 53.9 64.0 0.062
Myocardial Infarction, % 7.3 6.5 6.8 9.6 0.005 6.7 9.7 11.9 17.7 0.003
Heart failure, % 1.0 1.2 2.0 5.0 <0.001 3.3 3.4 4.7 11.4 <0.001
Stroke, % 8.5 7.6 8.0 9.5 0.235 12.2 18.9 14.0 19.5 0.125
Therapeutic measures
PCI, % 10.4 12.4 11.7 9.2 0.024 16.7 20.0 21.8 11.8 0.023
Thrombolytic therapy, % 57.6 54.7 54.2 45.6 <0.001 53.3 45.1 40.4 43.0 0.068
Insulin, % 11.4 9.5 11.8 13.8 0.002 42.8 37.1 37.9 42.3 0.548
β-blockers, % 45.8 67.3 69.5 68.0 <0.001 42.8 73.1 66.8 68.0 <0.001
ACEI, % 68.3 74.3 73.1 71.8 <0.001 63.3 73.1 75.7 78.3 0.004
Lipid-lowering drugs, % 69.7 73.6 71.6 69.3 0.023 71.7 76.0 73.1 70.6 0.644
PCI, Percutaneous coronary intervention; ACEI, Angiotensin-converting enzyme inhibitors; P-values are given for the comparison of between the different quartiles
of heart rate.
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of admission HR and prognosis. In patients without
T2DM, comparing with HR <66 b.p.m., the HR of 66–76
b.p.m., 77–88 b.p.m., or >88 b.p.m. demonstrate Hazard
Ratios of 1.44 (95% CI 1.13-1.84, P = 0.003), 1.41 (95% CI
1.10-1.80, P = 0.007), and 2.30 (95% CI 1.85-2.87, P < 0.001)
for 30-day all-cause mortality; while hazard ratios for 30-
day CVE were 1.39 (95% CI, 1.10-1.75, P = 0.005), 1.42
(95% CI 1.22-1.78, P = 0.003) and 2.30 (95% CI 1.87-2.83,
P < 0.001). And in patients with T2DM, the hazard ratios
for 30-day CVE were 1.75(95%CI), 1.92(95%CI), 3.00Table 3 30-day events stratified by heart rate quartiles
(Q1-Q4) in patients with and without T2DM
Variable Heart rate(b.p.m.) P-value
All Q1 Q2 Q3 Q4
Patients without T2DM
All-cause mortality (%) 9.6 6.9 7.0 8.0 17.3 <0.001
Cardiovascular events (%) 11.2 8.8 8.8 9.6 18.5 <0.001
Patients with T2DM
All-cause mortality (%) 15.7 9.4 11.4 13.0 24.6 <0.001
Cardiovascular events (%) 18.1 10.6 12.6 16.0 27.9 <0.001(95%CI) in the HR of 66–76 b.p.m., 77–88 b.p.m., and >88
b.p.m., respectively. Similar results were shown in the ana-
lyses of 30-day all-cause mortality (As is shown in Table 4),
although the hazard ratios in Q2 and Q3 groups were
non-significant, which seemed probably due to ineffi-
cient power with the relative small sample size in
patients with T2DM.
However, of note, there was a significant interaction
effect of HR and diabetic state on 30-day CVE mortal-
ity (P = 0.035), which indicated that increased heart
rate at any level is more deleterious for CVE in dia-
betic than non-diabetic individuals. The potential
interaction effect on all-cause mortality was not found
(P = 0.126).
Discussion
Our study is the first one to assess the association be-
tween admission HR and all-mortality and CVE in
STEMI patients when accompanied with or without
T2DM. The main results are summarized as follows:
1. In STEMI patients accompanied with T2DM, admis-
sion HR, 30-day all-cause mortality and rate of CVE








Figure 2 The Kaplan-Meier curves for survival (A and B) and survival free from CVE (C and D) by heart rate at admission in patients
without (A and C) or with (B and D) T2DM (blue, Q1 ≤ 66 bpm; red, 66 < Q2 ≤ 76; yellow, 77 ≤ Q3 ≤ 88; black, Q4 > 88b.p.m.; P-value
was calculated by log-rank test).
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prognosis in STEMI patients with or without T2DM.
3. After controlling for baseline and in-hospital
therapeutic confounders, the prognostic effect of HRble 4 Adjusted hazard ratios for heart rate at admission in p
Adm
Q1 Q2, HR(95%CI) P-value
tients without T2DM
l-cause mortality 1.00 1.44 (1.13-1.84) 0.003
rdiovascular events 1.00 1.39(1.10-1.75) 0.005
tients with T2DM
l-cause mortality 1.00 1.70(0.84-3.41) 0.139
rdiovascular events 1.00 1.75(0.92-3.33) 0.086was different between patients with T2DM and
without T2DM. In the T2DM patients, the hazard
ratios in Q2 and Q3 groups were non- significant,
however, it seemed probably due to inefficient poweratients with or without T2DM
ission heart rate(b.p.m.)
Q3, HR(95%CI) P-value Q4, HR(95%CI) P-value
1.41 (1.10-1.80) 0.007 2.30 (1.85-2.87) <0.001
1.42(1.22-1.78) 0.003 2.30(1.87-2.83) <0.001
1.84(0.95-3.59) 0.072 2.56(1.38-4.73) 0.003
1.92(1.05-3.48) 0.033 3.00(1.76-5.14) <0.001
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each increased HR group were larger in individuals
with than without T2DM, and there was a significant
interaction effect of HR and diabetic state on 30-day
CVE mortality (P = 0.035), which indicated that
increased heart rate at any level is more deleterious
for prognosis in diabetic than non-diabetic
individuals.
Previous studies have shown a positive association be-
tween elevated HR and increasing risk of cardiovascular
disease (CVD), all-cause and cardiovascular mortality in
general people and in patients with various cardiovascu-
lar diseases [1,3,14-16], especially AMI. Myocardial is-
chemia results from an imbalance between coronary
blood flow supply and myocardial metabolic demand.
HR and other determinants highly affect myocardial oxy-
gen demand [17], meanwhile, HR is the major determin-
ant of the supply of blood flow. Some studies [18] have
shown that elevated HR can stimulate the arterial wall,
affect local hemodynamic environment [19,20] activate
inflammation [21], disturb the imbalance between myo-
cardial demand and supply [22], and disrupt atheroscler-
otic plaques [23].
Concomitant T2DM then increases the aforemen-
tioned influence further when compared with patients
without T2DM, propensity to worse prognosis. First,
hyperglycemia may play an important role by several
pathophysiological mechanisms [24-27]. Secondly, these
patients have higher HR [28].
Some epidemiologic studies suggest the relationship be-
tween HR and outcome in diabetic patients. Stettler et al.
[29] have reported the prognostic role of HR in patients
with T2DM. In the Bremen Diabetes study, higher HR was
also related to an increase of cardiovascular death [30].
However, Anselmino et al. [31] reported that in patients
with stable CAD, the association between resting HR and
CVE can be found in those with diabetes, but not in non-
diabetic patients. It’s unknown if the difference retains in
acute settings, such as STEMI. Our observation performed
after separating T2DM from non-T2DM in STEMI
patients, which showed that HR was an independent risk
factor of prognosis (P < 0.05) regardless of T2DM.
Cardiac autonomic neuropathy (CAN) is a common
chronic complication of T2DM [32], and manifests an in-
crease in HR and a reduction in HR variability, that con-
fer higher morbidity and mortality to diabetic patients
[33,34]. CAN may contribute to the differences identified
in the present study. High HR is not considered to diag-
nose CAN by itself, but it can reflect a relative imbalance
in the sympathetic activity and vagal impairment [32].
It appears that T2DM and autonomic dysfunction are
causally related, and a higher HR, elevated high blood
pressure, and ischemia burden may be intermediateaccelerators [35]. So that, T2DM may strengthen the
predictive effect of HR by CAN, but we also need
further study of the internal mechanism to confirm this
hypothesis.
Our finding in more than 7 000 patients pointed out
that HR at admission was an independent predictor of
short-term adverse outcome, including cardiovascular
and all-cause mortality despite the high level of treat-
ment with beta-blockers. The results emphasized the dif-
ferent of prognostic effect of HR between the two kinds
of population, meanwhile. However, more prospective
studies are needed to confirm these findings in larger
clinical registries.Study limitation
First, the study is a subgroup analysis of an existing ma-
terial, and thereby suffers from limitations and biases of
such material. It is not totally equivalent to the real set-
tings. Second, we only observed the all-cause mortality
and CVE in 30 days; a longer follow-up may declare
more information and elucidate the hypothesis generated
in this report. Third, we don’t take blood glucose or gly-
colated hemoglobin level into account, which reflect the
therapeutic effect of T2DM, and may effect the degree of
CAN. And the HR in our database is only gained at ad-
mission rather than on-treatment or discharge value sim-
ultaneously. At last, the sample size of T2DM patients
was far less than patients without T2DM (~1/8), and
seemed to preclude statistical significance. A larger sam-
ple will be needed to improve the statistical power and
find out the truth.Conclusion
In conclusion, resting HR affects 30-day all-cause mortal-
ity and CVE in STEMI patients no matter with or with-
out T2DM. The adverse effect of HR is more obvious in
diabetic than non-diabetic individuals. When researching
HR and cardiovascular prognosis, T2DM status must be
considered. This is also useful in clinical study and
treatment.
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